TIDMANA
Ananda Developments PLC
10 May 2023
ANANDA DEVELOPMENTS PLC
Ananda's ambition is to be a leading UK grower and manufacturer
of consistent, high-quality medical cannabis for UK patients.
Medical Cannabis Research Roundup
Issue Nineteen
Summary:
The last month has seen more evidence of cannabis and its
constituents including the reviews of the pharmacological effects
of cannabidiol, its potential in eye health, prostatitis and
chronic pelvic pain and general chronic pain. To illustrate some of
the wide effect cannabis and some of its constituents such as
cannabidiol and terpenes we have chosen three papers on quite
different subjects.
The first is on acne, something that everyone can relate to.
What the study demonstrates is that cannabidiol (CBD) plus
terpenes, in this case from a pennywort, a traditional herbal
medicine plant, have a better effect than CBD by itself. This is
not surprising given the anti-microbial properties of terpenes and
the involvement of microbes in acne. Cannabis also contains
terpenes, so it is likely that a broad or full spectrum cannabidiol
topical might have similar effect.
Another example of the benefits of a broad or full spectrum of
cannabinoids and terpenes is shown in the paper on the synergistic
activity of THC and terpenes compared to THC alone in the second
paper.
The third paper exemplifies the benefits of CBD cannabis to
general health showing that people were better off in terms of less
d rowsiness lower diabetes higher testosterone.
Like many papers we have had in our Research Roundup before
these show the many activities of cannabis and/or its constituents
which is an example of the broad nature of the endocannabinoid
system.
Good for acne
Acne vulgaris, the most common form of acne, is characterized by
a mixed eruption of inflammatory and noninflammatory skin lesions
primarily affecting the face, upper arms, and trunk.
The pathogenesis of acne is multifactorial and includes abnormal
keratinization and plugging of the hair follicles, increased sebum
production, proliferation and activation of Cutibacterium acnes (C.
acnes; formerly Propionibacterium acnes, P. acnes), and finally
inflammation.
The first stage of the study investigated the capacity of
different plant extracts and plant extract combinations to reduce
C. acnes growth and decrease IL-1<BETA> and TNF<ALPHA>
secretion from U937 cells. The results found that Centella asiatica
triterpene (CAT) extract as well as silymarin (from Silybum
marianum fruit extract) had significantly superior
anti-inflammatory activity when combined with CBD compared to
either ingredient alone.
In addition, the CAT extract helped potentiate CBD-induced C.
acnes growth inhibition. The three ingredients were integrated into
a topical formulation and evaluated in ex vivo human skin organ
cultures. The formulation was found to be safe and effective,
reducing both IL-6 and IL-8 hypersecretion without hampering
epidermal viability.
Finally, a preliminary clinical study of this formulation
conducted on 30 human subjects showed a statistically significant
reduction in acne lesions (mainly inflammatory lesions) and
porphyrin levels, thereby establishing a tight correlation between
in vitro, ex vivo, and clinical results. Further studies must be
conducted to verify the results, including placebo-controlled
clinical assessment, to exclude any action of the formulation
itself.
Reference:
Development of an Effective Acne Treatment Based on CBD and
Herbal Extracts: Preliminary In Vitro, Ex Vivo, and Clinical
Evaluation (hindawi.com)
<https://www.hindawi.com/journals/ecam/2023/4474255/>
<https://dim.mcusercontent.com/cs/fd0e56ff0828ad1078ee6b45e/images/87262912-5e96-101e-7cbf-8aadef557dc8.jpeg?w=564&dpr=2>
Evidence of synergistic effects of THC and terpenes
There has long been talk of the entourage effect of full
spectrum cannabis and despite much discussion there has not been a
lot of follow up work to provide more evidence of it - particularly
in the entourage or synergy of cannabinoids and terpenes.
In this preprint of this study from Israel has provided in vitro
evidence of the synergistic activity of THC and various terpenes at
the CB1 receptor.
Importantly, the study showed this activity at the ratios of
terpenes to THC that appear in the plant. The amount of total
terpenes in cannabis flower tends to be approximately 2-3% w/w.
Commonly, the three or four major terpenes will amount to about 50%
of the total.
The results demonstrate that all terpenes, when tested
individually, activate CB1 receptors, at about 10-50% of the
activation by THC alone. The combination of some of these terpenes
with THC significantly increases the activity of the CB1 receptor,
compared to THC alone. In some cases, several fold.
For some terpenes, the activation obtained by THC- terpene
mixtures is notably greater than the sum of the activations by the
individual components, suggesting a synergistic effect. Our results
strongly support a modulatory effect of some of the terpenes on the
interaction between THC and the CB1 receptor.
As the most effective terpenes are not necessarily the most
abundant ones in the cannabis plant, reaching "whole plant" or
"full spectrum" composition is not necessarily an advantage. For
enhanced therapeutic effects, desired compositions are attainable
by enriching extracts with selected terpenes. These compositions
adjust the treatment for various desired medicinal and personal
needs.
Reference:
Selected Cannabis Terpenes Synergize with THC to produce
increased CB1 Receptor activation;
https://www.sciencedirect.com/science/article/pii/S0006295223001399?via%3Dihub
<https://dim.mcusercontent.com/cs/fd0e56ff0828ad1078ee6b45e/images/70b9532b-ec75-d00e-087d-546541a5f426.jpeg?w=564&dpr=2>
Self-Dosing CBD Use Found To Decrease Drowsiness, Diabetes &
Low Testosterone
As the number of people who use cannabidiol (CBD) increasingly
rises, regulatory bodies, such as the FDA (Food and Drug
Administration), are concerned about the use of CBD in adults. Data
from studies can be used to understand better the effects of CBD on
the liver, daytime drowsiness and testosterone levels and inform
dosing protocols.
A recent clinical study platform was used to collect data from
1,061 adults who self-dose with CBD. Customers from US CBD brands
were recruited via social media and sent a CBD product to use for
the study. Participants provided personal information, medical
history, reasons for taking CBD, present dosage, form and
composition of CBD, alcohol consumption and current medications and
conditions. They reported the effects of the CBD over 30 days in a
daily journal, after which blood samples were drawn and tested for
lover tests and testosterone levels in men.
Most of the participants used full-spectrum CBD oil or CBD
isolate. The average daily dose of CBD was 0.65 - 0.57 mg/kg/day,
which is typical. The daily dose of CBD consumed by participants
who used an oral, full-spectrum CBD product formulated using
nanotechnology was significantly lower than that of CBD isolate and
broad-spectrum CBD. 33 participants reported side effects, most of
which were probably unrelated to CBD ingestion.
In this large-sample study, individuals self-dosing CBD had
decreased daily drowsiness, decreased diabetes, and decreased low
testosterone, and no participants demonstrated liver disease. In
this study, older individuals taking CBD had a lower prevalence of
low testosterone and a lower prevalence of type 2 diabetes than the
general population. Clinical trials are needed to further assess
the safety of CBD in adults.
Reference:
The Effects of Long-Term Self-Dosing of Cannabidiol on
Drowsiness, Testosterone Levels, and Liver Function
https://www.karger.com/Article/Abstract/529677
The Directors of the Company accept responsibility for the
contents of this announcement.
ANANDA DEVELOPMENTS PLC +44 (0)7463 686 497
Chief Executive Officer
Melissa Sturgess
Investor Relations
Jeremy Sturgess-Smith
PETERHOUSE CAPITAL LIMITED +44 (0)20 7469 0930
Corporate Finance
Mark Anwyl
Corporate Broking
Lucy Williams
Duncan Vasey
About Ananda Developments
Ananda is an AQSE-listed medical cannabis company creating
UK-based operations to grow and provide carbon zero, consistent,
medical cannabis for the UK and international markets.
The UK medical cannabis market is predicted to be worth GBP450m
by 2025 and the European market is predicted to be worth USD4.2bn
by 2027.
For more information, please visit:
https://anandadevelopments.com/
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABSGDURGGDGXC
(END) Dow Jones Newswires
May 10, 2023 04:00 ET (08:00 GMT)
Ananda Developments (AQSE:ANA)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Ananda Developments (AQSE:ANA)
Historical Stock Chart
Von Mai 2023 bis Mai 2024